Your browser doesn't support javascript.
loading
NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders.
Mariotto, Sara; Gastaldi, Matteo; Grazian, Luisa; Mancinelli, Chiara; Capra, Ruggero; Marignier, Romain; Alberti, Daniela; Zanzoni, Serena; Schanda, Kathrin; Franciotta, Diego; Calabria, Francesca; Monaco, Salvatore; Reindl, Markus; Ferrari, Sergio; Gajofatto, Alberto.
  • Mariotto S; Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. Electronic address: sara.mariotto@gmail.com.
  • Gastaldi M; Laboratory of Neuroimmunology, IRCCS, National Neurological Insitute C. Mondino Foundation, Pavia, Italy.
  • Grazian L; Pediatric Unit, ULSS 2 Marca Trevigiana, Ca' Foncello Hospital, Treviso, Italy.
  • Mancinelli C; Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.
  • Capra R; Multiple Sclerosis Center, ASST - Spedali Civili of Brescia, Montichiari, Brescia, Italy.
  • Marignier R; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, and Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Alberti D; Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Zanzoni S; Centro Piattaforme Tecnologiche, University of Verona, Italy.
  • Schanda K; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Franciotta D; Laboratory of Neuroimmunology, IRCCS, National Neurological Insitute C. Mondino Foundation, Pavia, Italy.
  • Calabria F; Neurology Unit, AOUI Verona, Verona, Italy.
  • Monaco S; Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Reindl M; Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Ferrari S; Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Gajofatto A; Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Mult Scler Relat Disord ; 50: 102833, 2021 May.
Article en En | MEDLINE | ID: mdl-33601213
ABSTRACT
The unpredictable course and uncertain impact of relapses make treatment strategies of anti-myelin oligodendrocyte glycoprotein antibodies associated disorders (MOGAD) challenging. We analysed neurofilament light chain levels (NfL) in onset and follow-up sera of 18 patients with MOGAD to clarify the timing of axonal damage. In comparison with disease onset values (median 8.9 pg/mL, range 1.8-97), NfL levels remained stable or decreased in most follow-up measurements (n=52, median 6.7 pg/mL, range 0.2-207), including those measured on relapses. The predominant axonal damage occurs during onset, which could be the main driving factor of final disability, with subsequent relevant clinical and therapeutic implications.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Autoanticuerpos Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Autoanticuerpos Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article